WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 2 fonti

AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront

AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.

Raccontata da

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo2 g fa

AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront

AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.

thehindubusinessline.com2 g fa

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.

Leggi questa versione → originale

Timeline cronologica

martedì 14 luglio 2026·thehindubusinessline.com
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
martedì 14 luglio 2026·endpoints.news
AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront
AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.